Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
274 questions in 25 reviews · Movement Disorders
current versionsNo studies 13 · 4.7%Ungraded 7 · 2.6%Very low 66 · 24.1%Low 66 · 24.1%Moderate 87 · 31.8%High 35 · 12.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GLP‐1 receptor agonists vs no treatment HRQoL · adults with Parkinson's disease GLP‐1 receptor agonists for Parkinson's disease (2020) · Cochrane | no estimate extracted | 1 study · 44 participants | Very low |
GLP‐1 receptor agonists vs no treatment Serious adverse events. · adults with Parkinson's disease GLP‐1 receptor agonists for Parkinson's disease (2020) · Cochrane | RR 1.6 [0.4, 6.32] | 1 study · 44 participants | Very low |
GLP‐1 receptor agonists vs no treatment Adverse events ‐ weight loss · adults with Parkinson's disease GLP‐1 receptor agonists for Parkinson's disease (2020) · Cochrane | no estimate extracted | 1 study · 44 participants | Very low |
Iron vs placebo Change in IRLS severity scale score · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | no estimate extracted | 7 studies · 345 participants | Moderate |
Iron vs placebo Change in any measure of restlessness · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | no estimate extracted | 8 studies · 370 participants | Moderate |
Iron vs placebo Quality of life (dichotomous measure) · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | RR 2.01 [0.54, 7.45] | 2 studies · 39 participants | Very low |
Iron vs placebo Change in quality of life (continuous measure) · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | no estimate extracted | 3 studies · 128 participants | Very low |
Iron vs placebo Withdrew to use other RLS medication or because of inadequate RLS symptom control · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | RR 0.77 [0.41, 1.47] | 9 studies · 391 participants | Low |
Iron vs placebo Adverse events · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | RR 1.48 [0.97, 2.25] | 6 studies · 298 participants | Moderate |
Iron vs placebo Drop out due to adverse event · people with restless legs syndrome Iron for the treatment of restless legs syndrome (2019) · Cochrane | RR 1.91 [0.5, 7.26] | 9 studies · 398 participants | Low |
Deep brain stimulation vs sham stimulation Dystonia‐specific improvement · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Deep brain stimulation vs sham stimulation Quality of Life Assessmentusing SF‐36: mental health( · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Deep brain stimulation vs sham stimulation Functional capacity · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Deep brain stimulation vs sham stimulation Emotional assessment · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Low |
Deep brain stimulation vs sham stimulation Adverse Events · adults with dystonia (generalised, segmental, and cervical) Deep brain stimulation for dystonia (2019) · Cochrane | RR 1.58 [0.98, 2.54] | 2 studies · 102 participants | Very low |
Deep brain stimulation vs sham stimulation Tolerability · adults with dystonia (generalised, segmental, and cervical) Deep brain stimulation for dystonia (2019) · Cochrane | RR 1.86 [0.16, 21.57] | 2 studies · 102 participants | Very low |
Deep brain stimulation vs sham stimulation Subjective Evaluation of Clinical Status · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
Deep brain stimulation vs sham stimulation Quality of Life Assessment · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 33 participants | Low |
Deep brain stimulation vs sham stimulation Quality of Life Assessment · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |
Deep brain stimulation vs sham stimulation Functional Capacity · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Deep brain stimulation vs sham stimulation Emotional Assessment · adults with generalised or segmental dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Deep brain stimulation vs sham stimulation Dystonia‐specific symptoms ( · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Low |
Deep brain stimulation vs sham stimulation Clinical status( · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Low |
Deep brain stimulation vs sham stimulation Quality of Lifeusing SF‐36: physical functioning( · adults with cervical dystonia Deep brain stimulation for dystonia (2019) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Botulinum toxin vs Placebo Severity of motor tics (measured by videotape of tic count) · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Botulinum toxin vs Placebo Severity of phonic tics · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs Placebo Premonitory Urge (treated tics) · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Botulinum toxin vs Placebo Sensory tics · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs Placebo Adverse events · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Botulinum toxin vs Placebo Development of immunoresistance against botulinum toxin · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Functional disability ( · people with essential tremor Topiramate for essential tremor (2017) · Cochrane | no estimate extracted | 1 study · 223 participants | Very low |
Intervention NR Study withdrawal ( · people with essential tremor Topiramate for essential tremor (2017) · Cochrane | RR 1.78 [1.23, 2.6] | 2 studies · 285 participants | Low |
Intervention NR Adverse events ( · people with essential tremor Topiramate for essential tremor (2017) · Cochrane | no estimate extracted | 1 study · 221 participants | Low |
Zonisamide vs placebo Functional abilities Change in TRS part B score (motor tasks) Change in TRS part C score (functional disability) (higher scores indicate a better outcome) · participants with essential tremor Zonisamide for essential tremor (2017) · Cochrane | MD 0 | 1 study · 20 participants | Very low |
Zonisamide vs placebo Study withdrawal for any reason Number of participants withdrawn from the study · participants with essential tremor Zonisamide for essential tremor (2017) · Cochrane | RD 0.1 | 1 study · 20 participants | Very low |
Zonisamide vs placebo Adverse events Number of adverse events · participants with essential tremor Zonisamide for essential tremor (2017) · Cochrane | RD 0.6 [0.28, 0.92] | 1 study · 20 participants | Very low |
Botulinum toxin type A vs botulinum toxin type B Overall cervical dystonia improvement: change from baseline to week 4 · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | NR | Low |
Botulinum toxin type A vs botulinum toxin type B Participants with adverse events № of participants: 111 (1 RCT) · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 1.4 [1, 1.96] | NR | Low |
Botulinum toxin type A vs botulinum toxin type B Subjective change as assessed by the patient at week 4 · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | NR | Low |
Botulinum toxin type A vs botulinum toxin type B Cervical dystonia associated pain: change from baseline to week 2‐4 · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | NR | Low |
Botulinum toxin type A vs botulinum toxin type B Adverse events: sore throat/dry mouth № of participants: 212 (2 RCTs) · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 4.39 [2.43, 7.91] | NR | Moderate |
Botulinum toxin type A vs botulinum toxin type B Adverse events: dysphagia № of participants: 249 (3 RCTs) · adults with cervical dystonia Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 2.89 [0.8, 10.41] | NR | Low |
Botulinum neurotoxin B vs placebo Overall cervical dystonia improvement as · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | 3 studies · 316 participants | Moderate |
Botulinum neurotoxin B vs placebo Proportion of withdrawals due to adverse events · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 0.88 [0.19, 4.06] | 4 studies · 440 participants | Low |
Botulinum neurotoxin B vs placebo Cervical dystonia associated pain: change from baseline to week 4 as · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | 2 studies · 207 participants | Low |
Botulinum neurotoxin B vs placebo Subjective change as assessed by the patient at week 4 · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | no estimate extracted | 3 studies · 316 participants | High |
Botulinum neurotoxin B vs placebo Proportion of participants with adverse events · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 1.09 [0.97, 1.23] | 2 studies · 186 participants | Very low |
Botulinum neurotoxin B vs placebo Adverse events: dry mouth · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 7.65 [2.75, 21.32] | 4 studies · 438 participants | High |
Botulinum neurotoxin B vs placebo Adverse events: dysphagia · adults with cervical dystonia Botulinum toxin type B for cervical dystonia (2016) · Cochrane | RR 6.78 [2.42, 19.05] | 4 studies · 438 participants | High |
Opioids vs placebo RLS symptoms · RLS Opioids for restless legs syndrome (2016) · Cochrane | no estimate extracted | 1 study · 270 participants | Low |